120 related articles for article (PubMed ID: 3163797)
21. The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma.
Bast RC; Knapp RC
Important Adv Oncol; 1987; ():39-53. PubMed ID: 3331386
[No Abstract] [Full Text] [Related]
22. [A trial with immunotherapy of ovarian cancer by idiotype vaccination. Activation of the idiotype network in patients with advanced ovarian cancers by treatment with monoclonal antibody OC125].
Wagner U; Reinsberg J; Krebs D
Geburtshilfe Frauenheilkd; 1990 Oct; 50(10):785-8. PubMed ID: 2286317
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of new cancer-associated antigen CA125 II in epithelial ovarian cancers: comparison with CA125.
Kobayashi H; Tamura M; Satoh T; Terao T
Clin Biochem; 1993 Jun; 26(3):213-9. PubMed ID: 8330391
[TBL] [Abstract][Full Text] [Related]
24. CA125 antigen levels in obstetric and gynecologic patients.
Niloff JM; Knapp RC; Schaetzl E; Reynolds C; Bast RC
Obstet Gynecol; 1984 Nov; 64(5):703-7. PubMed ID: 6208522
[TBL] [Abstract][Full Text] [Related]
25. Isolation and characterization of blood group N antigen precursor glycoproteins with Thomsen-Friedenreich (T) activity, N antigen precursor glycoproteins and T-active glycoproteins from cyst fluids of malignant ovarian clear cell carcinoma.
Yanagi K; Ohyama K; Yamakawa T; Ohkuma S
Int J Biochem; 1990; 22(9):1015-28. PubMed ID: 2282960
[TBL] [Abstract][Full Text] [Related]
26. [Heterogeneity of the CA125 antigen that coexpresses sialyl Tn and CA19-9 antigens].
Kobayashi H; Ohi H; Shinohara H; Terao T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Sep; 45(9):980-6. PubMed ID: 8371024
[TBL] [Abstract][Full Text] [Related]
27. Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry.
Yuan M; Itzkowitz SH; Boland CR; Kim YD; Tomita JT; Palekar A; Bennington JL; Trump BF; Kim YS
Cancer Res; 1986 Sep; 46(9):4841-7. PubMed ID: 3731131
[TBL] [Abstract][Full Text] [Related]
28. Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids.
Karlan BY; Amin W; Casper SE; Littlefield BA
Cancer Res; 1988 Jun; 48(12):3502-6. PubMed ID: 3285997
[TBL] [Abstract][Full Text] [Related]
29. Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells.
Matsuoka Y; Nakashima T; Endo K; Yoshida T; Kunimatsu M; Sakahara H; Koizumi M; Nakagawa T; Yamaguchi N; Torizuka K
Cancer Res; 1987 Dec; 47(23):6335-40. PubMed ID: 3315184
[TBL] [Abstract][Full Text] [Related]
30. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
31. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer].
Liu W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823
[TBL] [Abstract][Full Text] [Related]
32. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
Taylor DD; Gercel-Taylor C; Parker LP
Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
[TBL] [Abstract][Full Text] [Related]
33. The potential value of CA125 as a tumour marker in small volume, non-evaluable epithelial ovarian cancer.
Cruickshank DJ; Terry PB; Fullerton WT
Int J Biol Markers; 1991; 6(4):247-52. PubMed ID: 1795133
[TBL] [Abstract][Full Text] [Related]
34. Tumor markers for ovarian cancer. A comparative immunohistochemical and immunocytochemical study of two commercial monoclonal antibodies (OV632 and OC125).
Koelma IA; Nap M; van Steenis GJ; Fleuren GJ
Am J Clin Pathol; 1988 Oct; 90(4):391-6. PubMed ID: 2459953
[TBL] [Abstract][Full Text] [Related]
35. Tn and sialyl-Tn antigens as potential prognostic markers in human ovarian carcinoma.
Ogawa H; Ghazizadeh M; Araki T
Gynecol Obstet Invest; 1996; 41(4):278-83. PubMed ID: 8793500
[TBL] [Abstract][Full Text] [Related]
36. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
37. p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer.
Heublein S; Page SK; Mayr D; Ditsch N; Jeschke U
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1163-70. PubMed ID: 26935926
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
Heublein S; Egger M; Zhu J; Berger L; Mayr D; Schindlbeck C; Kuhn C; Hofmann SS; Schuetz F; Jeschke U; Ditsch N
Breast Cancer Res Treat; 2020 Feb; 179(3):643-652. PubMed ID: 31828591
[TBL] [Abstract][Full Text] [Related]
39. Proliferating cell nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer?
Thomas H; Nasim MM; Sarraf CE; Alison MR; Love S; Lambert HE; Price P
Br J Cancer; 1995 Feb; 71(2):357-62. PubMed ID: 7841053
[TBL] [Abstract][Full Text] [Related]
40. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1992 Jan; 10(1):95-101. PubMed ID: 1727929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
